APREA THERAPEUTICS, INC.

3805 Old Easton Road

Doylestown, PA 18902

 

April 25, 2024

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Chris Edwards

 

Re:	Aprea Therapeutics, Inc.
	Registration Statement on Form S-3
	File No. 333-278485
	Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278485), so that it may become effective at 4:30 p.m. Eastern Time on April 29, 2024, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

 

The cooperation of the staff in meeting the timetable described above is very much appreciated.

 

Please call Fahd Riaz, Esq. of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement.

 

Very truly yours,
APREA THERAPEUTICS, INC.
By:	/s/ Oren Gilad
Name:	Oren Gilad
Title:	Chief Executive Officer

 

cc:	Patrick O’Malley, Esq., DLA Piper LLP (US)
	Dylan Caplan, Esq., DLA Piper LLP (US)